320 Views

CS01 - Breathing Innovation into Insulin Therapy: Latest Updates on Inhaled Insulin

Saturday, August 9, 2025

11:00 AM - 11:45 AM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE
Universal Activity Number (Live): JA4008258-0000-25-247-L01-P

Inhaled insulin represents a promising advancement in diabetes management, offering a potentially underrecognized option for insulin delivery. Despite the widespread use of traditional insulin methods, barriers such as injection discomfort, medication-taking issues, and less physiologic onset of action persist. Inhaled technosphere insulin, with its rapid onset and pharmacokinetics closer to physiologic prandial insulin release, addresses these challenges and provides an innovative alternative. This session will cover the history, pharmacology, pivotal clinical trials, and practical aspects of initiating and managing patients on inhaled insulin. Attendees will gain insights into the applications of inhaled insulin through case studies involving people with both type 1 and type 2 diabetes. By understanding the benefits and clinical evidence, healthcare professionals can enhance glycemic outcomes, improve medication-taking, and embrace new strategies in insulin therapy.

This session has been made possible through an independent educational grant generously provided by MannKind Corporation.

Disclosure(s):

Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES: Sanofi: Speaker/Honoraria (Ongoing)

Anders Carlson, MD: Abbott: Research Grant (Ongoing); Amgen: Research (Ongoing); Dexcom: Research Grant (Ongoing); Eli Lilly: Research Grant (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Luna: Research (Ongoing); Mannkind: Consultant / Advisory Board (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Sanofi: Research Grant (Ongoing); Tandem: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Zealand: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing)

Speaker(s)

Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES (he/him/his)

Endocrinology Clinical Pharmacy Specialist
Cleveland Clinic

Disclosure(s): Sanofi: Speaker/Honoraria (Ongoing)
Anders Carlson, MD (he/him/his)

Associate Executive Director
International Diabetes Center

Disclosure(s): Abbott: Research Grant (Ongoing); Amgen: Research (Ongoing); Dexcom: Research Grant (Ongoing); Eli Lilly: Research Grant (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Luna: Research (Ongoing); Mannkind: Consultant / Advisory Board (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Sanofi: Research Grant (Ongoing); Tandem: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing); Zealand: Consultant / Advisory Board (Ongoing), Research Grant (Ongoing)

Session Host(s)

Jodi M. Lavin-Tompkins, MSN, RN, BC-ADM, CDCES (she/her/hers)

Director of Accreditation & Content Development
Association of Diabetes Care & Education Specialists